Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VR-AD-1005
- Development stage
- Phase 2
- Lead developer
- Hunazine Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**VR-AD-1005** is an investigational oral antisecretory treatment for acute watery diarrhea caused by cholera. It is described as a fixed-dose, two-component formulation containing a cystic fibrosis transmembrane conductance regulator inhibitor and an intestinal-wall-adherent component intended to reduce convective washout in the gut. By inhibiting cystic fibrosis transmembrane conductance regulator activity that is persistently activated downstream of cholera toxin, it is intended to reduce intestinal chloride and water secretion, stool output, and rehydration requirements without impairing intestinal motility. The program originated at Vanessa Biotech and is being advanced by Hunazine Biotech; a completed Phase 2 study in Bangladesh was followed by a funded Phase 3 development project in sub-Saharan Africa. ([global-health-edctp3.europa.eu](https://www.global-health-edctp3.europa.eu/projects/hunadia_en))
- Other names
- VR
Beyond the preview
Go deeper on VR-AD-1005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VR-AD-1005.